Abeona Therapeutics Inc (NASDAQ:ABEO) Sees Significant Growth in Short Interest

Abeona Therapeutics Inc (NASDAQ:ABEOGet Rating) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,660,000 shares, an increase of 18.3% from the March 31st total of 3,940,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the short-interest ratio is presently 2.4 days.

NASDAQ:ABEO opened at $0.21 on Wednesday. The company has a market cap of $30.95 million, a PE ratio of -0.25 and a beta of 1.50. Abeona Therapeutics has a twelve month low of $0.21 and a twelve month high of $2.04. The company’s 50 day moving average is $0.28 and its two-hundred day moving average is $0.43.

Abeona Therapeutics (NASDAQ:ABEOGet Rating) last released its earnings results on Thursday, March 31st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $3.00 million for the quarter. As a group, research analysts anticipate that Abeona Therapeutics will post -0.33 earnings per share for the current fiscal year.

ABEO has been the topic of a number of analyst reports. StockNews.com initiated coverage on shares of Abeona Therapeutics in a research report on Wednesday, April 27th. They issued a “hold” rating on the stock. Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research report on Tuesday, April 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $1.75.

A number of large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new stake in Abeona Therapeutics during the 3rd quarter worth approximately $37,000. Millennium Management LLC lifted its stake in Abeona Therapeutics by 20.3% during the 4th quarter. Millennium Management LLC now owns 825,996 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 139,259 shares during the period. Geode Capital Management LLC lifted its stake in Abeona Therapeutics by 24.0% during the 3rd quarter. Geode Capital Management LLC now owns 814,919 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 157,898 shares during the period. Acadian Asset Management LLC acquired a new stake in Abeona Therapeutics during the 4th quarter valued at approximately $78,000. Finally, Virtu Financial LLC acquired a new stake in Abeona Therapeutics during the 4th quarter valued at approximately $84,000. 27.81% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile (Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

See Also

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.